Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Koninklijke Philips N.V. is a Dutch multinational health technology company founded in 1891, headquartered in Amsterdam, Netherlands. Originally starting with light bulb production, it has transformed into a leader in advancing healthcare through innovative solutions that span the health continuum from prevention and diagnosis to treatment and home care. The company operates through three main segments: Diagnosis & Treatment, featuring precision diagnostics and image-guided therapy like MRI, CT, and ultrasound scanners; Connected Care, encompassing patient monitoring, sleep and respiratory care, and health informatics; and Personal Health, offering products such as electric toothbrushes, shavers, and baby care items. With approximately 68,000 employees, operations in over 100 countries, and around 53,000 patents, Koninklijke Philips N.V. invests about 9-10% of its revenue—roughly €18 billion in 2024—into research and development. Its mission focuses on improving 2.5 billion lives annually by 2030, including underserved communities, solidifying its pivotal role in global medtech innovation and patient outcomes.
€23.93
+€0.29 (+1.23%)
EOD Jun 25, 2026 · Twelve Data
Operating margin is thin at 8.12%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 1.0% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 44% versus the prior year, cash generation momentum has weakened. Net debt of €5.02B represents 10.0x FCF, leverage limits flexibility.
23.3x earnings, 14.3x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€17.64B
▼ -1.0% YoY
Net Income (TTM)
€971M
▲ +228.5% YoY
Op. Margin
8.72%
▲ +5.3pp YoY
ROIC
5.76%
▲ +4.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€1.62B
▼ -43.6% YoY
Op. Cash Flow (TTM)
€2.56B
▼ -16.3% YoY
Net Debt
€5.02B
Cash & Equiv.
€2.79B
3Y CAGR: +0.0%
Continue Research
At a P/E of 23.3 and a price-to-free-cash-flow of 14.3, Koninklijke Philips (PHIA.XAMS) trades below a two-stage DCF intrinsic value of about €52.30 per share, so at €23.93 the stock looks undervalued (118.6% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Koninklijke Philips scores 50/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.4%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about €52.30 per share for PHIA.XAMS, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around €39.23. At today's €23.93, that puts the stock about 118.6% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Koninklijke Philips scores 50 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 8.7% operating margin and a 5.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Koninklijke Philips pays a regular dividend of about €0.34 per share per year (typically in quarterly installments), a yield of roughly 1.4% at the current price. That is a payout ratio of about 33.8% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For PHIA.XAMS's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. PHIA.XAMS currently trades below its estimated intrinsic value and scores 50/100 on quality (mixed). It also yields about 1.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.